Overview Dividends

(CYRX) Cryoport - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2290503075

Cryogenic Freezers, Cryogenic Dewars, Accessories, Shipping Systems, Biostorage

CYRX EPS (Earnings per Share)

EPS (Earnings per Share) of CYRX over the last years for every Quarter: "2020-09-30": -0.29, "2020-12-31": -0.26, "2021-03-31": -0.13, "2021-06-30": -0.16, "2021-09-30": -0.18, "2021-12-31": -0.11, "2022-03-31": -0.31, "2022-06-30": -0.23, "2022-09-30": -0.15, "2022-12-31": -0.24, "2023-03-31": -0.16, "2023-06-30": -0.42, "2023-09-30": -0.31, "2023-12-31": -1.31, "2024-03-31": -0.43, "2024-06-30": -0.29, "2024-09-30": -0.02, "2024-12-31": -0.4271, "2025-03-31": -0.3836, "2025-06-30": 2.05,
EPS Growth (3Y CAGR): 46.19%
EPS Trend (3Y Correlation): 37.4%

CYRX Revenue

Revenue of CYRX over the last years for every Quarter: 2020-09-30: 11.172084, 2020-12-31: 48.361, 2021-03-31: 53.284, 2021-06-30: 56.191, 2021-09-30: 56.693, 2021-12-31: 56.44, 2022-03-31: 52.302, 2022-06-30: 64.153, 2022-09-30: 60.464, 2022-12-31: 60.358, 2023-03-31: 62.817, 2023-06-30: 57.021, 2023-09-30: 56.157, 2023-12-31: 57.26, 2024-03-31: 54.592, 2024-06-30: 57.597, 2024-09-30: 56.664, 2024-12-31: 59.532, 2025-03-31: 41.04, 2025-06-30: 45.454,
Revenue Growth (3Y CAGR): -9.86%
Revenue Trend (3Y Correlation): -71.0%

Description: CYRX Cryoport

Company Overview

Cryoport Inc a leading provider of temperature-controlled supply chain solutions in the biopharma/pharma, health, and medicine markets. The expertise lies in providing cryogenic logistics and biostorage services.

The company operates through two main segments segments: Life Sciences Services and Life Sciences Sciences Products. The revenue is generated through a mix of service offerings and product sales, catering to the life sciences industry.

Notably, Cryoport has established itself as a a major player in the biopharmaceutical logistics space, with a strong presence in the the US market. The companys has shown significant growth, driven by increasing demand for temperature-controlled logistics and biostorage services.

Key Performance Indicators (KPIs) such as Revenue Growth Rate, Customer Acquisition Cost,, and Customer Retention Rate are crucial in evaluating the companys performance business performance. Additionally, metrics like the Gross Margin and Operating Expenses as a Percentage of Revenue provide insights into the operational the efficiency.

With a Market Capitalization of $366. With a forward P/E ratio of 58 58.14, the stock is trading at a premium, indicating high growth expectations.

The information provided offers a comprehensive overview of the the companys business model, market presence, and financial performance. The analysis highlights the importance of temperature-controlled logistics and biostorage services in the life sciences sciences industry and Cryoports a major player in this this space. The key takeaway is that Cryoport is well-positioned for for future growth, driven by increasing demand for its its services and products. in the biopharmaceutical logistics industry.

CYRX Stock Overview

Market Cap in USD 444m
Sub-Industry Health Care Equipment
IPO / Inception 2005-03-15

CYRX Stock Ratings

Growth Rating -48.3%
Fundamental 21.2%
Dividend Rating -
Return 12m vs S&P 500 -8.66%
Analyst Rating 4.0 of 5

CYRX Dividends

Currently no dividends paid

CYRX Growth Ratios

Growth Correlation 3m 84.9%
Growth Correlation 12m 0%
Growth Correlation 5y -94.2%
CAGR 5y -32.08%
CAGR/Max DD 3y -0.38
CAGR/Mean DD 3y -0.59
Sharpe Ratio 12m -1.46
Alpha 0.03
Beta 0.756
Volatility 89.19%
Current Volume 517k
Average Volume 20d 517.8k
Stop Loss 8.4 (-6.6%)
Signal 0.41

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (75.3m TTM) > 0 and > 6% of Revenue (6% = 12.2m TTM)
FCFTA -0.04 (>2.0%) and ΔFCFTA 1.02pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 226.6% (prev 196.0%; Δ 30.66pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.02 (>3.0%) and CFO -16.7m <= Net Income 75.3m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 16.24 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (50.1m) change vs 12m ago 1.53% (target <= -2.0% for YES)
Gross Margin 45.73% (prev 37.94%; Δ 7.78pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 24.93% (prev 26.47%; Δ -1.54pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -12.91 (EBITDA TTM -5.56m / Interest Expense TTM 2.73m) >= 6 (WARN >= 3)

Altman Z'' -1.93

(A) 0.59 = (Total Current Assets 489.5m - Total Current Liabilities 30.1m) / Total Assets 773.9m
(B) -0.86 = Retained Earnings (Balance) -668.2m / Total Assets 773.9m
(C) -0.04 = EBIT TTM -35.2m / Avg Total Assets 813.1m
(D) -2.58 = Book Value of Equity -668.2m / Total Liabilities 258.5m
Total Rating: -1.93 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 21.22

1. Piotroski 2.0pt = -3.0
2. FCF Yield -16.16% = -5.0
3. FCF Margin -16.57% = -6.21
4. Debt/Equity 0.37 = 2.43
5. Debt/Ebitda -34.19 = -2.50
6. ROIC - WACC (= -12.16)% = -12.50
7. RoE 17.37% = 1.45
8. Rev. Trend -70.99% = -5.32
9. EPS Trend 37.44% = 1.87

What is the price of CYRX shares?

As of September 17, 2025, the stock is trading at USD 8.99 with a total of 517,035 shares traded.
Over the past week, the price has changed by -8.73%, over one month by +2.28%, over three months by +29.73% and over the past year by +8.44%.

Is Cryoport a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Cryoport (NASDAQ:CYRX) is currently (September 2025) a stock to sell. It has a ValueRay Fundamental Rating of 21.22 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CYRX is around 7.06 USD . This means that CYRX is currently overvalued and has a potential downside of -21.47%.

Is CYRX a buy, sell or hold?

Cryoport has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CYRX.
  • Strong Buy: 4
  • Buy: 2
  • Hold: 4
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CYRX price?

Issuer Target Up/Down from current
Wallstreet Target Price 12.1 34.7%
Analysts Target Price 12.1 34.7%
ValueRay Target Price 7.7 -14.2%

Last update: 2025-09-03 04:35

CYRX Fundamental Data Overview

Market Cap USD = 443.6m (443.6m USD * 1.0 USD.USD)
CCE Cash And Equivalents = 426.0m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 58.1395
P/S = 1.8648
P/B = 0.9297
Beta = 1.881
Revenue TTM = 202.7m USD
EBIT TTM = -35.2m USD
EBITDA TTM = -5.56m USD
Long Term Debt = 185.8m USD (from longTermDebt, last quarter)
Short Term Debt = 4.32m USD (from shortTermDebt, last quarter)
Debt = 190.1m USD (Calculated: Short Term 4.32m + Long Term 185.8m)
Net Debt = -14.9m USD (from netDebt column, last quarter)
Enterprise Value = 207.8m USD (443.6m + Debt 190.1m - CCE 426.0m)
Interest Coverage Ratio = -12.91 (Ebit TTM -35.2m / Interest Expense TTM 2.73m)
FCF Yield = -16.16% (FCF TTM -33.6m / Enterprise Value 207.8m)
FCF Margin = -16.57% (FCF TTM -33.6m / Revenue TTM 202.7m)
Net Margin = 37.16% (Net Income TTM 75.3m / Revenue TTM 202.7m)
Gross Margin = 45.73% ((Revenue TTM 202.7m - Cost of Revenue TTM 110.0m) / Revenue TTM)
Tobins Q-Ratio = -0.31 (set to none) (Enterprise Value 207.8m / Book Value Of Equity -668.2m)
Interest Expense / Debt = 0.33% (Interest Expense 618.0k / Debt 190.1m)
Taxrate = 21.0% (US default)
NOPAT = -35.2m (EBIT -35.2m, no tax applied on loss)
Current Ratio = 16.24 (Total Current Assets 489.5m / Total Current Liabilities 30.1m)
Debt / Equity = 0.37 (Debt 190.1m / last Quarter total Stockholder Equity 515.4m)
Debt / EBITDA = -34.19 (Net Debt -14.9m / EBITDA -5.56m)
Debt / FCF = -5.66 (Debt 190.1m / FCF TTM -33.6m)
Total Stockholder Equity = 433.7m (last 4 quarters mean)
RoA = 9.73% (Net Income 75.3m, Total Assets 773.9m )
RoE = 17.37% (Net Income TTM 75.3m / Total Stockholder Equity 433.7m)
RoCE = -5.68% (Ebit -35.2m / (Equity 433.7m + L.T.Debt 185.8m))
RoIC = -5.92% (NOPAT -35.2m / Invested Capital 594.5m)
WACC = 6.24% (E(443.6m)/V(633.7m) * Re(8.80%)) + (D(190.1m)/V(633.7m) * Rd(0.33%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 90.91 | Cagr: 0.29%
Discount Rate = 8.80% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -33.6m)
EPS Correlation: 37.44 | EPS CAGR: 46.19% | SUE: 4.0 | # QB: 1
Revenue Correlation: -70.99 | Revenue CAGR: -9.86% | SUE: N/A | # QB: None

Additional Sources for CYRX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle